Inhibitor Therapeutics, Inc. (OTCMKTS:INTI – Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 320 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 29,580 shares, the days-to-cover ratio is currently 0.0 days.
Inhibitor Therapeutics Stock Performance
INTI remained flat at $0.08 on Monday. 1 shares of the company traded hands, compared to its average volume of 14,653. The stock has a market cap of $13.90 million, a price-to-earnings ratio of -8.00 and a beta of -0.73. Inhibitor Therapeutics has a 12-month low of $0.04 and a 12-month high of $0.12. The stock’s 50-day simple moving average is $0.09 and its two-hundred day simple moving average is $0.08.
Inhibitor Therapeutics Company Profile
Inhibitor Therapeutics is a development-stage pharmaceutical company focused on investigating treatments for cancer. Its work includes repurposing itraconazole, an established antifungal medicine, for potential use in cancer treatment. The company has pursued development of itraconazole for prostate cancer and basal cell carcinoma. These are investigational uses; itraconazole’s existing approval as an antifungal does not mean it is approved to treat cancer.
Further Reading
- Five stocks we like better than Inhibitor Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
